ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy

This study is currently recruiting participants.
Study NCT00524797.   Last updated on September 2, 2007.   Information provided by Ziv Hospital

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Official Title  Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
Brief Summary

Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. Death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs) are widely used in the treatment of chemotherapy induced neutropenia. The same Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments are expensive and have several side effects.

In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life.

The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia.

This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.

Detailed Description
Study Phase
Study Type  Interventional
Study Design  Prevention, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Myelosuppression
Intervention  Dietary Supplement: Profonycia
MEDLINE PMIDs 17303914
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  50
Start Date  September 2007
Completion Date
Eligibility Criteria 

Inclusion Criteria:

Patients 18 years old or elder receiving chemotherapy 1/2-3 weeks

Exclusion Criteria:

Patients below 18 years old

Gender Both
Ages 18 Years to 80 Years
Accepts Healthy Volunteers No
Contacts ††
Contact: Zidan Jamal, Prof     +972 4 6828951        
Location Countries  Israel
Administrative Information Fields
NCT ID  NCT00524797
Organization ID HP 7-260 S
Secondary IDs ††
Study Sponsor  Ziv Hospital
Collaborators ††
Investigators 
Principal Investigator:     Zidan Jamal, Prof     Ziv MC    
Information Provided By Ziv Hospital
Verification Date September 2007
First Received Date  September 2, 2007
Last Updated Date September 2, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers